Novartis asks FDA for Galvus review extension

Novartis has asked the FDA to extend the review period for its highly anticipated developmental diabetes drug Galvus by three months to allow the agency to examine new clinical trials data.

3M sheds pharma unit for $2.1 billion

3M has agreed to sell-off its global pharmaceuticals business, which makes dermatology, women’s health, cardiology and respiratory treatments, for $2.1 billion.

Abbott to buy Kos for $3.7 billion

Abbott has agreed to buy specialty firm Kos for $3.7 billion, a move that complements its cardiovascular franchise and boosts its pipeline.

HealthMedia acquires

Behavioral change-focused relationship marketing firm HealthMedia announced today that it has acquired the consumer Web site